Navigation Links
Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
Date:1/7/2009

THOUSAND OAKS, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will present at the 27th Annual JP Morgan Global Healthcare Conference at 9:00 a.m. Pacific Time on Monday, Jan. 12, 2009, at the Westin St. Francis in San Francisco, Calif. Amgen Chairman and CEO Kevin Sharer will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)

Information regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

    CONTACT: Amgen, Thousand Oaks
    David Polk, 805-447-4613 or 805-490-0661 (media)
    Arvind Sood, 805-447-1060 (investors)


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... -- Albany Molecular Research Inc. (NASDAQ: AMRI ) ... President and Chief Executive Officer, will present at the ... on Wednesday, May 13, 2015 at 4:20 p.m. ET. ... can be accessed at AMRI,s Investor Relations web site at ... be archived for 90 days following the live presentation. ...
(Date:4/30/2015)... 01, 2015 Spirax Sarco, the leader ... proud to announce that for the first time in ... winner of a Queen’s Award for Innovation – the ... and manufacture of a unique flowmeter. , The Spirax ... to traditional steam flow measurement. The device provides ...
(Date:4/30/2015)... April 30, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... of 2015 were $4.4 million, compared to $8.0 million during ... the first quarter was $8.9 million, or $0.23 per basic ... for the same period in 2014, of $8.7 million, or ... 31, 2015, cash, cash equivalents and investments totaled $117.5 million. ...
(Date:4/30/2015)... ALEXANDRIA, Va. , April 30, 2015 ... provides senior debt to life sciences and healthcare services ... senior secured term loan agreement with Celula, Inc., a ... diagnosing major diseases, enabling better patient care and improved ... continue the development and expand the commercialization of its ...
Breaking Biology Technology:AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Oxford Finance Provides $10 Million Debt Financing to Celula 2
... 23 ArunA Biomedical, Inc., announced ... MN, giving Neuromics the right to non-exclusively market ... and Neural Culture Medium to support applications in ... an exclusive worldwide license to develop and commercialize ...
... 23 BioDuro and AstraZeneca announced today that ... discovery research for Respiratory and Inflammation indications. BioDuro ... of discovery chemistry, discovery biology, ADMET*, and DMPK** ... discovery and shorten development timelines. "After a successful ...
... Nereus Pharmaceuticals, Inc., a pioneer in drug discovery ... is conducting a randomized Phase 2 clinical trial ... combination with standard chemotherapy (docetaxel) in patients with ... follows on positive outcomes in the Phase 1 ...
Cached Biology Technology:ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells 2BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications 2Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer 2Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer 3
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
(Date:3/31/2015)... 2015  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ... Software Defined Network Architecture (ET Software DNA® 2.0) platforms ... approximately $20.4 million for the year ended December 31, ... the year ended December 31, 2013. ... completed its multi-year transition away from its legacy landline ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... have uncovered how members of one family of antibiotics ... knowledge may help drug developers make slight changes to ... strains of bacteria, said Irina Artsimovitch, a study co-author ... University. , The antibiotics studied belong to the rifamycin ...
... Rice University, the Baylor College of Medicine, the University of ... have created a new class of magnetic resonance imaging (MRI) ... than the best in clinical use. , The new agents ... gadolinium, that is given to more than a quarter of ...
... About five to seven million years ago, when the ... similar to rutabagas and turnips may have been one ... Laden of the University of Minnesota and Richard Wrangham ... organs like roots and tubers must have sustained our ...
Cached Biology News:Researchers find how some antibiotics kill bacteria 2Researchers find how some antibiotics kill bacteria 3'Gadonanotubes' greatly outperform existing MRI contrast agents 2The roots of civilization trace back to ... roots 2
... Cy5 Post-Labeling Reactive Dye Pack, ... CyDye fluors specifically optimized for microarray ... 40000 pmol reactive dye per vial, ... to use, individually dispensed, and packed ...
... with CyScribe GFX Purification Kit, 24 ... of Cy3- and Cy5-labeled cDNA.Optimized reagents ... labeling and purification.Flexible and optimized protocols ... reactions with either Cy3- or Cy5-labeled ...
... ISO 9001:2000 Certified USDA Research Registered OLAW ... Training AALAS Certified Technicians ... GLP Documentation Upon Request Focus ... for all your custom immunology service needs. ...
NORMAL DONOR DONKEY SERUM...
Biology Products: